Skip to content

Home
About Us
Clinical Trials
Science & Technology
Pipeline
Investor Relations
Resources
Patient Resources
Contact

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026

Share this post

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

follow us

Linkedin Youtube Twitter

Contact Us

5850 San Felipe St., Suite 500 Houston, TX 77057 USA

+1 800-587-8170

© 2026 Coya Therapeutics, Inc. All rights reserved.

Privacy Policy
Terms & Conditions

Biotech Website Design